Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Recruiting
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
Recruiting
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCCEED) Study, which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). No patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPD... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Pancreatitis
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Recruiting
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
04/25/2025
Locations: Texas Children's Cancer and Hematology Center, Houston, Texas
Conditions: Von Willebrand Disease
A Study of PHST001 in Advanced Solid Tumors
Recruiting
PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumors
Mothers and CareGivers Investing in Children Study 2.0
Recruiting
The study will use a longitudinal, randomized control trial design to determine intervention impact on parent and child behaviors, and infant health. The two intervention groups include: 1) MAGIC-FEED+; and 2) MAGIC-SAFE. This trial is an efficacy trial of the MAGIC-FEED and MAGIC-SAFE program that has been successfully implemented with families as part of the MAGIC 1.0 program trial (IRB#: 2015040017). * The primary aim is to investigate each intervention's impact on infant BMIZ at 13 months.... Read More
Gender:
ALL
Ages:
Between 0 years and 90 years
Trial Updated:
04/24/2025
Locations: Sarah M. & Charles E. Seay Building, Austin, Texas
Conditions: Childhood Obesity Prevention, Parenting Behavior, Infant Growth
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems
Recruiting
To compare narrow-angle digital breast tomosynthesis (DBT) and wide-angle DBT.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/24/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Architectural Distortions, Breast Tomosynthesis
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/24/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Hidradenitis Suppurativa
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Recruiting
This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
04/24/2025
Locations: Methodist Children's Hospital, San Antonio, Texas
Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring
Recruiting
This pilot study uses a state-of-the-science combination of remote behavioral monitoring, real-time experience sampling, in-lab physiological assessments, and extraction of neighborhood-level characteristics to (1) Examine the impact of daily experience (i.e., racial discrimination, affective states, stress) on health behaviors (i.e., physical activity, sedentary behavior, sleep) at the intrapersonal level among Black women; (2) Test the association between daily behaviors and impairments in bio... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/24/2025
Locations: The University of Texas at Arlington, Arlington, Texas
Conditions: Cardiovascular Diseases, Heart Disease Risk Factors
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
Recruiting
To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Recruiting
This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and eva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: NEXT Oncology, Austin, Texas
Conditions: Cancer